CG Oncology (CG Oncology) Other Current Liabilities : $2.01 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Other Current Liabilities?

CG Oncology's other current liabilities for the quarter that ended in Mar. 2024 was $2.01 Mil.

CG Oncology's quarterly other current liabilities declined from Sep. 2023 ($3.35 Mil) to Dec. 2023 ($3.27 Mil) and declined from Dec. 2023 ($3.27 Mil) to Mar. 2024 ($2.01 Mil).

CG Oncology's annual other current liabilities increased from Dec. 2021 ($1.13 Mil) to Dec. 2022 ($2.01 Mil) and increased from Dec. 2022 ($2.01 Mil) to Dec. 2023 ($3.27 Mil).

CG Oncology Other Current Liabilities Historical Data

The historical data trend for CG Oncology's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Other Current Liabilities Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Other Current Liabilities

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

CG Oncology Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

CG Oncology Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of CG Oncology's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024